An International Learning Collaborative Phase II Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease

Investigator conducted an international multicenter Phase II clinical trial testing the hypothesis that non-myeloablative related haploidentical BMT with thiotepa and post-transplant cyclophosphamide will result in two-year event-free survival of at least 80%.